IQVIA vet takes the helm at China's Fountain Medical; Michael Nazak promoted to CFO post at Aridis
→ After bagging $62 million in a Series D financing round, Fountain Medical Development has tapped IQVIA vet Ling Zhen as CEO and co-chairman of the board of directors. Most recently, Zhen served as a partner at Draper Dragon Venture Group. During his time at IQVIA (formerly Quintiles), Zhen served as a global SVP and general manager of Greater China. Prior to IQVIA, Zhen served at Eli Lilly, GSK and Ernst & Young in the US.
→ Microcap Aridis Pharmaceuticals — who last October snagged Takeda vet Paul Mendelman to man the company as interim CMO after a Phase II flop — has promoted Michael Nazak to CFO. Nazak is succeeding Fred Kurland, who is retiring. Nazak joined the company in November 2018 as VP, finance. Prior to Aridis, Nazak was the SVP, finance at Coherus Biosciences. His previous stints include serving as senior director of finance and accounting at InteKrin Therapeutics and as corporate controller at Reliant Technologies.
→ DBV Technologies, who in October announced that the FDA had accepted its latest BLA filing for its peanut allergy patch, has named Ramzi Benamar as CFO. Benamar joins the company from Spark Therapeutics, where he served as VP and head of financial planning and analysis. Benamar’s prior experience includes roles at Merck, Johnson & Johnson and Shire.
→ NuVasive — focused on spine technology — has appointed Matthew Harbaugh as EVP and CFO, who will succeed Rajesh Asarpota. Most recently, Harbaugh was president of Mallinckrodt, where he also formerly served as the company’s CFO. His other stints include roles at Covidien Pharmaceuticals and Monsanto Company.
→ Following a $24 million Series B financing round, healthcare platform company Vim has tapped Mike Leonard as chief revenue officer. Prior to his appointment at Vim, Leonard was the CCO at Castlight Health. Before that, Leonard was the EVP of sales and marketing at Jiff (purchased by Castlight in April 2017).
→ Enzo Biochem has appointed Rebecca Fischer to its board of directors to succeed retiring Gregory Bortz. Fischer is the CFO of Bellevue Hospital.
→ Texas-based cancer drug developer Plus Therapeutics welcomed An van Es-Johansson, the chief medical officer for AlzeCure Pharma, an Alzheimer’s-focused Swedish company to its board on January 1.
→ Titan Pharmaceuticals — whose lead product Probuphine is used for long-term maintenance treatment of opioid dependence — has elected the company’s EVP and CSO, Kate DeVarney, to its board of directors.